Mechanism · Research Data · Side Effects · No Doses
Ipamorelin nudges the pituitary into releasing your own growth hormone, and the main research finding is that it does this without the cortisol and appetite spikes older GH-releasing peptides cause. That selectivity is backed by animal and early human data. There is also a genuinely separate human RCT thread on it speeding up gut recovery after bowel surgery, which is a different use case entirely from bodybuilding. As always, no doses are published here, and this page does not provide a protocol.
| Evidence Type | Status |
|---|---|
| Human RCT | ✔ |
| Observational | ✗ |
| Animal Studies | ✔ |
| In Vitro | ✔ |
| Regulatory Approval | ✗ |
Research indicates that Ipamorelin effectively stimulates the pituitary gland to secrete endogenous growth hormone. Studies in animal models and early human trials have consistently shown dose-dependent increases in plasma GH levels following Ipamorelin administration. This effect is observed without a significant rise in other pituitary hormones like ACTH, prolactin, or cortisol, suggesting a unique selectivity amongst ghrelin mimetics.
Due to its ability to support growth hormone secretion, Ipamorelin has been investigated in animal models for its potential influence on body composition. Studies have explored its role in modulating muscle protein synthesis and fat metabolism, indirectly mediated by increased GH and subsequent IGF-1 levels. Research suggests an association with increased lean body mass and decreased adipose tissue in specific experimental settings.
The impact of Ipamorelin on bone metabolism has been explored in various preclinical studies. Given that growth hormone and insulin-like growth factor-1 (IGF-1) play crucial roles in bone formation and remodeling, researchers have investigated whether Ipamorelin-induced GH secretion could contribute to enhanced bone mineral density or support bone repair processes in animal models.
As a ghrelin receptor agonist, Ipamorelin's effects extend beyond GH release, with some research focusing on its potential influence on gastrointestinal function. Early human clinical trials investigated Ipamorelin's role in postoperative ileus, a condition characterized by delayed gut motility after surgery. These studies aimed to assess whether Ipamorelin could accelerate gastric emptying and restore normal bowel function.
Endogenous growth hormone is released in a pulsatile pattern that follows the sleep-wake cycle, with the largest natural pulses occurring during deep, slow-wave sleep. Because Ipamorelin's secretagogue action depends on stimulating the pituitary's own GH release rather than replacing it, research interest has focused on whether administration timed around the sleep window amplifies this naturally-occurring nocturnal pulse rather than working against it. Direct human sleep-study data isolating this timing effect for Ipamorelin specifically remains limited.
| Study / Model | Reported Effect |
|---|---|
| Rat Pituitary Cells (In vitro) | Potent GH release with an EC50 of approximately 1.3 nM, demonstrating high specificity. |
| Healthy Human Volunteers (Phase II study) | Dose-dependent increases in GH Area Under Curve (AUC) by up to 13-fold compared to placebo. |
| Animal Model (muscle wasting) | Observed reduction in muscle protein breakdown markers and improved nitrogen balance. |
| Human Clinical Trials (postoperative ileus) | Demonstrated acceleration of gastric emptying time by approximately 23% compared to placebo in some patient populations. |
| Rat Model (bone healing) | Increased IGF-1 levels and improved bone mechanical strength parameters in fracture repair models. |
No severe adverse events consistently reported in available peer-reviewed literature for Ipamorelin in the context of controlled research settings.
Sport status: Ipamorelin is named under S2.2.4 and prohibited at all times. See the WADA 2026 Prohibited List.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide in the growth hormone releasing peptide (GHRP) class. It works as a selective agonist at the ghrelin receptor (GHS-R1a), which stimulates the pituitary gland to release the body's own growth hormone.
Is Ipamorelin legal in Ireland?
Ipamorelin is not an authorised medicine in Ireland. Advertising unauthorised human medicines is prohibited; supply and import are subject to legal restrictions. Check current HPRA and Revenue guidance.
How is Ipamorelin different from older GHRPs like GHRP-6 or Hexarelin?
The main research finding that sets Ipamorelin apart is selectivity. Published studies report that it stimulates GH release from the pituitary without meaningfully raising cortisol, prolactin or ACTH, effects that older GHRPs such as GHRP-6 and Hexarelin are reported to produce.
What does the research say about Ipamorelin and body composition?
Animal model research has explored Ipamorelin's indirect effect on body composition, mediated through GH and downstream IGF-1 signalling, with some studies reporting associations with increased lean mass and reduced adipose tissue in specific experimental settings. This is preclinical evidence, not an approved human indication.
More evidence-based peptide research guides, free.
Browse the Research GuidesTracking food too? Calorie counter with barcode scanner →
